Oragenics Appoints Key Hires to Drive Lantibiotic Platform Growth and Expansion

Transformative Lantibiotic Platform to Treat Various Life-Threatening Infectious Diseases

TAMPA, Fla.-- Oragenics, Inc. (NYSE: OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced two new appointments to the Product Development team. Joining the company are Guojun (Shawn) Nie Ph.D., as Director of Process Development, and Mr. Joel Ngoje as Senior Process Scientist. Together, the two bring almost 40 years of pharmaceutical, protein and process development experience to the company. Encouraging progress from the development of Oragenics’ novel Lantibiotic platform has necessitated the accelerated expansion of the R & D team to position the pipeline for clinical success.

Dr. Nie joins Oragenics with extensive industrial experience in the preclinical, clinical and late stage manufacturing activities at large CMOs (global reach) and clinical manufacturing for GMP production, including process design and development, improvement and optimization strategies, downstream development, scale-up, and technology transfer. Prior to joining Oragenics, Dr. Nie was most recently Senior Scientist, Process Development at Caliber Biotherapeutics. Prior to that, Dr. Nie held various positions in product development at GenVec Inc., Human Genome Sciences, Inc. and Baxter International, Inc.

Mr. Joel Ngoje joins Oragenics with comprehensive industrial experience in upstream and downstream protein purification process development as well as process optimization and scale-up from pilot to full-scale manufacturing. Prior to joining Oragenics, Mr. Ngoje worked as a Product Development Engineer in various research capacities at Celgene Corporation, VaxInnate Corporation, BioDelivery Sciences International, Inc. and Alpharma Inc.

Albert Fosmoe, Sr. VP Operations and Product Development of Oragenics, said, “We are thrilled to have these outstanding individuals on board to further empower our development team as we deliver on our vision to transform the lives of patients with innovative new antibiotics.”

John N. Bonfiglio, Ph.D., President and Chief Executive Officer of Oragenics added, “Shawn and Joel bring a wealth of product and process development experience to the company at an important inflection point. Our new team members will be instrumental to the success of our Lantibiotic platform and the further advancement of our drug candidate pipeline.”

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc. (NYSE: XON), a synthetic biology company. The collaborations will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in more than 13 countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on Facebook and Twitter.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in the filings of Intrexon and Oragenics with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.

Oragenics, Inc.
John N. Bonfiglio, PhD, 813-286-7900
Chief Executive Officer
Investor / Media Contacts
The Ruth Group
David Burke, 646-536-7000

Source: Oragenics, Inc.